Gene therapy in cystic fibrosis

Area of Science:

• Genetics and Molecular Biology
• Medical Genetics
• Biochemistry

Background:

• Cystic fibrosis (CF) is an autosomal recessive disorder resulting from mutations in the cystic fibrosis transmembrane regulator (CFTR) gene.
• It is the most prevalent life-shortening genetic defect among Caucasian populations.
• Significant advancements in treating end-organ complications have improved life expectancy in CF patients over the past 75 years.

Purpose of the Study:

• To review the nomenclature of CFTR mutations.
• To discuss various gene therapy approaches for CF, including viral and nonviral methods.
• To highlight recent progress in developing mutation-specific molecules for CF treatment.

Main Methods:

• Literature review of CFTR mutation nomenclature.
• Analysis of published studies on viral and nonviral gene therapy for CF.
• Review of recent research on mutation-specific molecules targeting CFTR.

Main Results:

• Over 1900 CF-causing CFTR mutations have been identified since 1989.
• Gene therapy efforts, while not yet yielding a cure, have illuminated key challenges in efficacy.
• Recent advances include the development of molecules targeting specific CFTR mutations.

Conclusions:

• Understanding CFTR mutation nomenclature is crucial for research and clinical applications.
• Gene-based therapies face hurdles but provide valuable insights into CF pathogenesis.
• Mutation-specific molecules represent a promising avenue for future CF therapeutics.